RESUMO
CASE REPORT: A 14-year-old girl from Peru suffered severe limbitis and conjunctivitis. She also presented with clinical skin features diagnosed as actinic prurigo (AP). Her symptoms were successfully controlled with sustained topical therapy of 2% Cyclosporine A. DISCUSSION: AP is an idiopathic photodermatosis that affects mainly the hispanic population of Latin America. There are ocular signs of severe limbitis and conjunctivitis (like atopic keratoconjunctivitis) in 45% of cases. Literature on the subject is very limited and currently topical cyclosporine seems to be the best therapy available.
Assuntos
Conjuntivite/tratamento farmacológico , Ciclosporina/administração & dosagem , Prurigo/tratamento farmacológico , Administração Tópica , Adolescente , Conjuntivite/complicações , Feminino , Humanos , Luz/efeitos adversos , Prurigo/complicações , Prurigo/etiologiaRESUMO
Caso clínico: Presentamos el caso de una mujer de 14 años latinoamericana, con una limbo-conjuntivitis severa. Habia sido diagnosticada de prúrigo actínico (PA) por el dermatólogo. Con el diagnóstico de PA ocular se inició tratamiento con colirio de ciclosporina A 2% con buena respuesta. Discusión: El PA es una fotodermatosis idiopática que afecta principalmente a la población mestiza de Latino América. Los ojos se ven afectados en el 45% de los casos, como una limbo-conjuntivitis severa semejante a la atópica. A pesar de la escasa bibliografía existente, la ciclosporina tópica representa la mejor alternativa en el tratamiento del PA ocular
Case report: A 14-year-old girl from Peru suffered severe limbitis and conjunctivitis. She also presented with clinical skin features diagnosed as actinic prurigo (AP). Her symptoms were successfully controlled with sustained topical therapy of 2% Cyclosporine A. Discussion: AP is an idiopathic photodermatosis that affects mainly the hispanic population of Latin America. There are ocular signs of severe limbitis and conjunctivitis (like atopic keratoconjunctivitis) in 45% of cases. Literature on the subject is very limited and currently topical cyclosporine seems to be the best therapy available
